Hyphen BioMed Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
100
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
Hyphen BioMed General Information
Description
Operator of a technical and innovative scientific company intended to propose a full line of diagnostic and research reagents to be distributed worldwide. The company offers medical, pharmaceutical research and hospital laboratories innovative tools for research and specialized biological diagnostics for thrombosis, hemostasis and auto-immune diseases, enabling the company to conceive, manufacture, market and develop research and biomedical in vitro diagnostic reagents for the exploration of thrombosis.
Contact Information
Website
www.hyphen-biomed.com(Operating Subsidiary)
Corporate Office
- 155 Rue D Eragny
- 95000 Neuville sur Oise
- France
Corporate Office
- 155 Rue D Eragny
- 95000 Neuville sur Oise
- France
Hyphen BioMed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hyphen BioMed Patents
Hyphen BioMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-2908892-A1 | Chromogenic determination of factor viii:c activity, comprises adding substance comprising at least one metal ion except calcium ion, potentiating the determination of the factor viii:c activity, identified as being present in plasma | Active | 21-Nov-2006 | ||
| FR-2908892-B1 | Process for the chromogenic assay of factor viii: c activity and need for chromogenic assay of factor viii: c activity in plasmas or therapeutic fractions | Inactive | 21-Nov-2006 | ||
| US-20100015647-A1 | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pahtologies potentiated by heparin such as heparin-induced thrombocytopenia | Active | 23-Jun-2006 | ||
| AU-2007262869-A1 | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia | Inactive | 23-Jun-2006 | ||
| CA-2655582-A1 | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia | Active | 23-Jun-2006 | G01N33/86 |
Hyphen BioMed Signals
Hyphen BioMed Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hyphen BioMed FAQs
-
When was Hyphen BioMed founded?
Hyphen BioMed was founded in 1999.
-
Where is Hyphen BioMed headquartered?
Hyphen BioMed is headquartered in Neuville sur Oise, France.
-
What is the size of Hyphen BioMed?
Hyphen BioMed has 100 total employees.
-
What industry is Hyphen BioMed in?
Hyphen BioMed’s primary industry is Distributors (Healthcare).
-
Is Hyphen BioMed a private or public company?
Hyphen BioMed is a Private company.
-
What is Hyphen BioMed’s current revenue?
The current revenue for Hyphen BioMed is .
-
Who are Hyphen BioMed’s investors?
IDF Capital and Naxicap Partners have invested in Hyphen BioMed.
-
When was Hyphen BioMed acquired?
Hyphen BioMed was acquired on 01-Jun-2010.
-
Who acquired Hyphen BioMed?
Hyphen BioMed was acquired by Sysmex (Diagnostic Equipment).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process